Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$304 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
6.2
Industry P/E
--
EV/EBITDA
0.4
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.7
Face value
--
Shares outstanding
77,114,600
CFO
$-286.26 Mln
EBITDA
$-344.37 Mln
Net Profit
$-334.34 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
| -26.5 | 8.9 | -16.7 | 103.6 | 55.3 | 4.1 | -- |
|
BSE Sensex
| 4.1 | -1.1 | 9.8 | 5.8 | 16.6 | 19.4 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
| 201.2 | 107.1 | -64.7 | -32.3 | -34.6 | 48.2 | -64.4 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Corvus Pharmaceuticals (CRVS)
|
3.9 | 303.8 | 0.0 | -41.4 | -- | -134.1 | -- | 6.2 |
| 50.1 | 8,093.9 | 1,208.8 | 131.7 | 13.4 | 6.3 | 61.9 | 4.0 | |
| 128.1 | 8,293.4 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 145.3 | 7,417.9 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 52.3 | 10,095.9 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 40.7 | 11,385.6 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19 | 5.3 | |
| 302.7 | 8,650.6 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23 | 14.4 | |
| 25.4 | 10,055.3 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 127.3 | 12,370.7 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.3 | 4.9 | |
| 291.7 | 13,016.0 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 11.5 | 1.9 |
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's... lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California. Address: 901 Gateway Boulevard, South San Francisco, CA, United States, 94080 Read more
Co-Founder, President, CEO & Chairman of the Board
Dr. Richard A. Miller M.D.
Co-Founder, President, CEO & Chairman of the Board
Dr. Richard A. Miller M.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Corvus Pharmaceuticals Inc (CRVS) stood at $ 69 Mln as on 31-Mar-25
The share price of Corvus Pharmaceuticals Inc (CRVS) is $3.93 (NASDAQ) as of 18-Jun-2025 16:00 EDT. Corvus Pharmaceuticals Inc (CRVS) has given a return of 55.26% in the last 3 years.
Corvus Pharmaceuticals Inc (CRVS) has a market capitalisation of $ 304 Mln as on 18-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Corvus Pharmaceuticals Inc (CRVS) is 6.16 times as on 18-Jun-2025, a 124% premium to its peers’ median range of 2.75 times.
Since, TTM earnings of Corvus Pharmaceuticals Inc (CRVS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Corvus Pharmaceuticals Inc (CRVS) and enter the required number of quantities and click on buy to purchase the shares of Corvus Pharmaceuticals Inc (CRVS).
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California. Address: 901 Gateway Boulevard, South San Francisco, CA, United States, 94080
The CEO & director of Dr. Richard A. Miller M.D.. is Corvus Pharmaceuticals Inc (CRVS), and CFO & Sr. VP is Dr. Richard A. Miller M.D..
There is no promoter pledging in Corvus Pharmaceuticals Inc (CRVS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,247
|
|
|
1,229
|
|
|
1,130
|
|
|
1,073
|
|
|
1,050
|
|
|
869
|
|
|
827
|
|
|
808
|
|
|
742
|
| Corvus Pharmaceuticals Inc. (CRVS) | Ratios |
|---|---|
|
Return on equity(%)
|
-134.12
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Corvus Pharmaceuticals Inc (CRVS) was $0 Mln.
$-0.01
(
